Markets:

Overview

News

Currencies

International

Treasuries

Harmony Biosciences Holdings, Inc. - Common Stock (NQ:HRMY)

35.46 -0.34 (-0.95%)

Streaming Delayed Price Updated: 12:27 PM EDT, Jul 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Harmony Biosciences Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Harmony Biosciences Holdings (NASDAQ:HRMY): A Growth Stock with a Promising Technical Setup ↗

October 16, 2025

Harmony Biosciences (HRMY) offers strong growth, high profitability, and an attractive valuation. Its positive technical setup suggests a potential breakout, making it a compelling stock to watch.

Via Chartmill

Top 3 Health Care Stocks That Are Preparing To Pump In Q4 ↗

October 06, 2025

Via Benzinga

Harmony Biosciences Holdings (NASDAQ:HRMY) Presents an 'Affordable Growth' Opportunity ↗

September 26, 2025

Harmony Biosciences (HRMY) offers affordable growth with strong EPS & revenue expansion, a low P/E ratio, and robust profitability in rare neurological treatments.

Via Chartmill

Deep Dive Into Harmony Biosciences Hldgs Stock: Analyst Perspectives (6 Ratings) ↗

September 25, 2025

Analysts' ratings for Harmony Biosciences Hldgs (NASDAQ: HRMY) over the last quarter vary from bullish to bearish, as provided by 6 analysts. Summarizing their recent assessments, the table below...

Via Benzinga

Freeport-McMoRan, Harmony Biosciences, Cohu, And Other Big Stocks Moving Lower On Wednesday ↗

September 24, 2025

Via Benzinga

Earnings Scheduled For August 5, 2025 ↗

August 05, 2025

Via Benzinga

Harmony Biosciences Stock Slumps After Rare Genetic Disorder Drug Fails Late-Stage Study ↗

September 24, 2025

The company said on Wednesday that its drug did not meet the primary endpoint of the trial primarily due to a higher-than-expected placebo response rate.

Via Stocktwits

Harmony Biosciences' Genetic Disorder Drug Disappoints In Phase 3 Study ↗

September 24, 2025

Harmony Biosciences' ZYN002 failed to meet its primary goal in a Fragile X Phase 3 trial, but the company points to pipeline growth.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

September 24, 2025

Via Benzinga

Harmony Biosciences Whiffs In 'Undruggable' Genetic Disease; Shares Tumble ↗

September 24, 2025

Shares plunged Wednesday as the inherited disease continued to be "undruggable" for the biotech company.

Via Investor's Business Daily

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

September 24, 2025

Via Benzinga

Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome

September 24, 2025

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Value Investment Opportunity ↗

September 18, 2025

Harmony Biosciences (HRMY) is a value stock with strong fundamentals: low P/E, high profitability, robust financial health, and impressive growth prospects.

Via Chartmill

Harmony Biosciences Holdings (NASDAQ:HRMY) Emerges as a Top Affordable Growth Stock ↗

September 04, 2025

Harmony Biosciences (HRMY) exemplifies GARP investing with strong EPS growth, a low P/E ratio, and robust profitability in the rare neurology sector.

Via Chartmill

Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress

August 26, 2025

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Value Investment Opportunity ↗

August 22, 2025

Harmony Biosciences (HRMY) is a value stock with strong fundamentals: undervalued P/E, high profitability, robust financial health, and impressive growth metrics.

Via Chartmill

Harmony Biosciences to Participate in 2025 Cantor Global Healthcare Conference

August 21, 2025

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences Holdings (NASDAQ:HRMY): A Prime Affordable Growth Stock with Strong Fundamentals ↗

August 13, 2025

Harmony Biosciences (HRMY) offers strong growth, solid valuation, and financial health, making it an ideal pick for Affordable Growth investors seeking high potential at reasonable prices.

Via Chartmill

Harmony Biosciences Holdings (NASDAQ:HRMY): A Strong Growth Stock with Promising Technical Setup ↗

August 09, 2025

Harmony Biosciences (HRMY) offers strong growth potential with solid fundamentals, high profitability, and a bullish technical setup, making it an attractive stock for investors.

Via Chartmill

Harmony Biosciences Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data From Phase 3 Registrational Trial in Q3 2025

August 05, 2025

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Value Investment Opportunity with Strong Fundamentals and Growth Potential ↗

July 26, 2025

Harmony Biosciences (HRMY) is undervalued with strong fundamentals—low P/E, high profitability, solid financials, and robust growth, making it a prime value investing opportunity.

Via Chartmill

Harmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025

July 22, 2025

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences Holdings (NASDAQ:HRMY) – A Strong Growth Stock with Attractive Valuation ↗

July 19, 2025

Harmony Biosciences (HRMY) offers strong growth, solid profitability, and an attractive valuation, making it a compelling choice for investors seeking affordable growth stocks in the pharmaceutical...

Via Chartmill

Harmony Biosciences to Participate in H.C. Wainwright "HCW@Home" Series

July 15, 2025

From Harmony Biosciences

Via Business Wire

6 Analysts Assess Harmony Biosciences Hldgs: What You Need To Know ↗

July 10, 2025

Via Benzinga

Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity ↗

July 10, 2025

Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal.

Via Investor's Business Daily

Topics Intellectual Property

HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) – An Undervalued Stock with Strong Fundamentals ↗

July 02, 2025

HARMONY BIOSCIENCES (HRMY) is an undervalued pharmaceutical stock with strong profitability, financial health, and growth potential, making it a candidate for value investors.

Via Chartmill

HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) - A Strong Candidate for Affordable Growth Investors ↗

June 27, 2025

HARMONY BIOSCIENCES (HRMY) offers strong growth, solid profitability, and an attractive valuation, making it a compelling choice for investors seeking affordable growth stocks in the pharmaceutical...

Via Chartmill

Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025

June 11, 2025

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences Holdings (NASDAQ:HRMY) – A Potentially Undervalued Stock in the Pharmaceutical Sector ↗

June 11, 2025

Harmony Biosciences (HRMY) presents a compelling value opportunity with strong profitability, financial health, and growth—all at an attractive valuation.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.